2001 OPEN FORUM Abstracts
ANALYSIS OF CROSS-CONTAMINATIONOF METERED DOSE INHALERS WHEN USING THE RESPIRONICS OPTICHAMBER UNDER THE COMMONCANISTER PROTOCOL.
William V. Wojciechowski, MS, RRT,Howard C. Maddox, Amanda L. Moseley. University of South Alabama, Mobile, Alabama.
Introduction: Many respiratorytherapy departments have implemented the common canister protocol (ccp) as acost-saving mechanism. The purpose of this study was to investigate the safetyof administering MDI medications among patients when using the Respironics OptiChamberunder the ccp.
Methods: Data were collectedfrom patients receiving MDI medications at the University of South Alabama KnollwoodPark Hospital (USAKPH), a 250-bed teaching hospital where the ccp is used. Thestudy involved surveillance of a sequence of three specimen collections obtainedfrom each patient. Specimen collections (specimens A, B, & C), obtainedon BBL?CultureSwabs? were cultured on two different media: sheep?s blood andchocolate agar, and analyzed for growth at 24, 48, and 72 hours of incubation.Specimen A was obtained from the MDI mouthpiece following swabbing with an alcoholpad before the MDI mouthpiece was attached to the OptiChamber. Specimen B wasobtained from the same location after the MDI mouthpiece was removed from theOptiChamber, following the administration of the medication. Specimen C wasobtained from the MDI mouthpiece after swabbing it with an alcohol pad followingthe removal of the MDI mouthpiece from the OptiChamber. MDI medications administeredincluded Ventolin (albuterol), Atrovent (ipratropium bromide), Flovent (fluticasone),and Serevent (salmeterol). Patients who were in isolation or receiving mechanicalventilation were not included in this study.
Results: The sample subjectprofile included a total of 50 patients. The 150 (50 patients x 3 cultures/patient)cultured samples demonstrated no growth at 24, 48, and 72 hours of incubation.
Conclusion: Cross-contaminationusing MDIs among patients in conjunction with the Respironics OptiChamber underthe ccp did not occur. Therefore, the ccp is a safe method for administeringmedications via MDIs using the Respironics OptiChamber. A significant reductionin purchase costs of MDIs is also possible when implementing the ccp. For example,the University of South Alabama Medical Center, which does not use the ccp andspends about $36,144.00/year on MDI medications, would save approximately $19,879.00/yearusing the ccp.